Sacubitril/Valsartan complex
| Status | Pipeline |
| Development phase | |
| Therapeutic cat. | Cardiology |
| Polymorphic form | Crystalline |
| CAS No. | 936623-90-4 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Sacubitril and valsartan is a combination medicine that is used in adults with chronic heart failure. Sacubitril and valsartan helps lower the risk of needing to be hospitalized when symptoms get worse, and helps lower the risk of death from heart failure. Sacubitril and valsartan is also used to treat heart failure in children who are at least 1 year old.
Polpharma API
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulationare met.
